Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection

• Status: Not yet recruiting
• Trial end date: 2023-05-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Apixaban is effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients after Laparoscopic Splenectomy and Azygoportal Disconnection

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guo-Qing Jiang
• Treatments: Apixaban; Dalteparin; Dipyridamole; Heparin; Heparin, Low-Molecular-Weight; Tinzaparin

Criteria

Inclusion Criteria:

1. A clinical, radiological or histologic diagnosis of cirrhosis of any etiology

2. Splenomegaly with secondary hypersplenism

3. Bleeding portal hypertension

4. No evidence of PVT or spleno-mesenteric thrombosis by ultrasound evaluation and angio-CT

5. Informed consent to participate in the study

Exclusion Criteria:

1. Hepatocellular carcinoma or any other malignancy,

2. Hypercoagulable state other than the liver disease related

3. DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.

4. Child - Pugh C

5. Recent peptic ulcer disease

6. History of Hemorrhagic stroke

7. Pregnancy.

8. Uncontrolled Hypertension

9. Human immunodeficiency virus (HIV) infection